Clinical Evaluation of the PowerGlide™ Pro Midline Catheter

NCT ID: NCT06037525

Last Updated: 2023-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases. The selected patients are in need of a long-term i.v. therapy for reasons as antibiotic therapy or alprostadil therapy. The Midline catheter is a device, which is placed via Seldinger's technique to a vein usual on the upper extremity under ultrasound-control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Catheter Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PowerGlide™ Pro Midline Catheter

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* need for i.v. therapy longer than 7 days
* poor peripheral vein status
* Administration of alprostadil

Exclusion Criteria

* pending dialysis
* allergy to catheter material
* minor age
* life threatening conditions
* requirement for central venous catheter
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Augsburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexander Hyhlik-Duerr, PhD

Role: STUDY_DIRECTOR

University Hospital Augsburg Vascular Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Augsburg

Augsburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MIDLINE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ClearWay™ RX Registry Trial
NCT00804024 COMPLETED
Citadel Embolization Device Study
NCT04057352 ACTIVE_NOT_RECRUITING NA